Key Metrics
Avg P/E Ratio
10.3
Profitable Companies
100%
Avg Growth
0.0%
Avg Dividend Yield
2.71%
Historical Return
1 Year
-9.7%
+2.7% Div
3 Years Ø
-9.5%
+2.7% Div
5 Years Ø
-5.8%
+2.7% Div
1 Year
+7.3%
+2.7% Div
3 Years Ø
+11.4%
+2.7% Div
5 Years Ø
+3.5%
+2.7% Div
Risk & Analysis Metrics
Volatility
91.74%
1 Year
69.99%
3 Years
38.37%
5 Years
32.69%
10 Years
Max Drawdown
-36.42%
1 Year
-51.84%
3 Years
-25.64%
5 Years
-29.42%
10 Years
Sharpe Ratio
1.07
1 Year
0.41
3 Years
0.46
5 Years
0.50
10 Years
Volatility
18.03%
1 Year
25.99%
3 Years
19.95%
5 Years
42.23%
10 Years
Max Drawdown
-9.86%
1 Year
-59.18%
3 Years
-31.55%
5 Years
-99.28%
10 Years
Sharpe Ratio
1.20
1 Year
-0.34
3 Years
0.49
5 Years
-0.69
10 Years
Return Triangle (Heatmap)
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011 | 8.3% | -39.6% | -29.3% | -17.2% | -21.2% | -16.6% | -12.3% | -12.4% | -10.2% | -9.4% | -8.2% | -5.3% | -5.4% | -5.3% | -6.1% |
| 2012 | -66.3% | -42.8% | -24.3% | -27.2% | -20.8% | -15.4% | -15.0% | -12.3% | -11.1% | -9.7% | -6.4% | -6.5% | -6.3% | -7.0% | |
| 2013 | -2.9% | 13.5% | -5.8% | -2.0% | 1.8% | -0.8% | 0.6% | 0.3% | 0.8% | 3.6% | 2.6% | 2.1% | 0.5% | ||
| 2014 | 32.6% | -7.2% | -1.6% | 3.0% | -0.4% | 1.2% | 0.8% | 1.3% | 4.4% | 3.2% | 2.5% | 0.8% | |||
| 2015 | -35.1% | -15.3% | -5.4% | -7.2% | -4.2% | -3.7% | -2.6% | 1.3% | 0.4% | -0.1% | -1.7% | ||||
| 2016 | 10.6% | 14.3% | 4.5% | 5.7% | 4.2% | 4.3% | 8.0% | 6.0% | 4.8% | 2.5% | |||||
| 2017 | 18.1% | 1.6% | 4.1% | 2.6% | 3.1% | 7.5% | 5.4% | 4.1% | 1.7% | ||||||
| 2018 | -12.7% | -2.3% | -2.0% | -0.4% | 5.5% | 3.4% | 2.3% | -0.2% | |||||||
| 2019 | 9.3% | 3.7% | 4.1% | 10.6% | 6.9% | 5.0% | 1.7% | ||||||||
| 2020 | -1.5% | 1.6% | 11.1% | 6.4% | 4.2% | 0.5% | |||||||||
| 2021 | 4.7% | 18.0% | 9.1% | 5.6% | 0.9% | ||||||||||
| 2022 | 33.0% | 11.4% | 6.0% | -0.1% | |||||||||||
| 2023 | -6.6% | -5.4% | -9.2% | ||||||||||||
| 2024 | -4.2% | -10.4% | |||||||||||||
| 2025 | -16.2% |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011 | 10.3% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2012 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| 2013 | - | - | - | - | - | - | - | - | - | - | - | - | - | ||
| 2014 | - | - | - | - | - | - | - | - | - | - | - | - | |||
| 2015 | - | - | - | - | - | - | - | - | - | - | - | ||||
| 2016 | - | - | - | - | - | - | - | - | - | - | |||||
| 2017 | - | - | - | - | - | - | - | - | - | ||||||
| 2018 | - | - | - | - | - | - | - | - | |||||||
| 2019 | - | - | - | - | - | - | - | ||||||||
| 2020 | - | - | - | - | - | - | |||||||||
| 2021 | - | - | - | - | - | ||||||||||
| 2022 | - | - | - | - | |||||||||||
| 2023 | - | - | - | ||||||||||||
| 2024 | - | - | |||||||||||||
| 2025 | - |
Distributions
Last updated: Oct 15, 2026Profit Margin Distribution
P/E Ratio Distribution
Discounted Cash Flow
Weighted Average Undervaluation
N/A
Undervalued
Overvalued
Equal Weight Average Undervaluation
N/A
Undervalued
Overvalued
Portfolio Concentration
99.8%
Top 5 Holdings
100.0%
Top 10 Holdings
100.0%
Top 50 Holdings
100.0%
Top 100 Holdings
Top 5 Companies
Market Cap Size Distribution
Micro: < $300M
Small: $300Mā$2B
Mid: $2Bā$10B
Large: $10Bā$200B
Mega: > $200B
Micro: < $300M
Small: $300Mā$2B
Mid: $2Bā$10B
Large: $10Bā$200B
Mega: > $200B
Latest News
View all news →
about 2 months ago
• benzinga.com
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics Inc. (NASDAQ:DYN) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR s...
about 2 months ago
• 247wallst.com
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) h...
about 2 months ago
• reuters.com
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling inves...
Average metrics of all companies in sector Last updated: Oct 25, 2026
Compare to Market
| Market Cap The average market value of companies in this sector. | $17.6T | |
| Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. | 2.71 % | |
| Beta Indicates the relationship between the price performance of a share and the market. | 0.5 | |
| P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. | 10.27 | |
| Negative P/E Ratio A negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything. | - | |
| Profitable Companies | 100% | |
| PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. | - | |
| Price to Sales Ratio Market cap divided by the revenue in the most recent year. | 1.37 | |
| Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company. | 1.56 |
Compare to Market
| Enterprise Value to EBIT Enterprise Value divided by EBIT. | 20.86 | |
| Enterprise Value to Revenue Enterprise value divided by revenue. | 4.14 | |
| Total Debt to Enterprise Value Total debt divided by enterprise value. | 0.03 | |
| Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. | 0.08 | |
| Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. | 10.75% | |
| Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. | +0.0% | |
| Return on Equity Equity divided by market cap. | 12.74% | |
| Return on Assets Indicates a company's profitability in relation to its total assets. | 8.90% | |
| Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. | 14.41% |
Stock Screener
Select filters to narrow down the 53 companies below
53 companies
Market Cap
$32.58T
Dividends
2.8%
P/E Ratio
9.0
Revenue
$9.87T
+19.9%
Net Income
$897B
-0.1%
Profit Margin
+9.1%
Employees
12.81K
View Stock
Market Cap
$32.58T
Dividends
2.8%
P/E Ratio
9.0
Revenue
$9.87T
+19.9%
Net Income
$897B
-0.1%
Profit Margin
+9.1%
Employees
12.81K
View Stock
Market Cap
$32.58T
Dividends
2.8%
P/E Ratio
9.0
Revenue
$9.87T
+19.9%
Net Income
$897B
-0.1%
Profit Margin
+9.1%
Employees
12.81K
View Stock
Market Cap
$2.62T
Dividends
1.9%
P/E Ratio
25.6
Revenue
$15.4B
+6.4%
Net Income
$2.51B
+2.3%
Profit Margin
+16.3%
Employees
96.1K
View Stock
Market Cap
$2.62T
Dividends
1.9%
P/E Ratio
25.6
Revenue
$15.4B
+6.4%
Net Income
$2.51B
+2.3%
Profit Margin
+16.3%
Employees
96.1K
View Stock
Market Cap
$2.62T
Dividends
1.9%
P/E Ratio
25.6
Revenue
$15.4B
+6.4%
Net Income
$2.51B
+2.3%
Profit Margin
+16.3%
Employees
96.1K
View Stock
Market Cap
$2.62T
Dividends
1.9%
P/E Ratio
25.6
Revenue
$15.4B
+6.4%
Net Income
$2.51B
+2.3%
Profit Margin
+16.3%
Employees
96.1K
View Stock
Market Cap
$2.62T
Dividends
1.9%
P/E Ratio
25.6
Revenue
$15.4B
+6.4%
Net Income
$2.51B
+2.3%
Profit Margin
+16.3%
Employees
96.1K
View Stock
Market Cap
$392.65B
Dividends
2.5%
P/E Ratio
25.4
Revenue
$30.2B
-5.2%
Net Income
$6.83B
-7.8%
Profit Margin
+22.6%
Employees
103.25K
View Stock
Market Cap
$392.65B
Dividends
2.5%
P/E Ratio
25.4
Revenue
$30.2B
-5.2%
Net Income
$6.83B
-7.8%
Profit Margin
+22.6%
Employees
103.25K
View Stock
Market Cap
$392.65B
Dividends
2.5%
P/E Ratio
25.4
Revenue
$30.2B
-5.2%
Net Income
$6.83B
-7.8%
Profit Margin
+22.6%
Employees
103.25K
View Stock
Market Cap
$392.65B
Dividends
2.5%
P/E Ratio
25.4
Revenue
$30.2B
-5.2%
Net Income
$6.83B
-7.8%
Profit Margin
+22.6%
Employees
103.25K
View Stock
Market Cap
$392.65B
Dividends
2.5%
P/E Ratio
25.4
Revenue
$30.2B
-5.2%
Net Income
$6.83B
-7.8%
Profit Margin
+22.6%
Employees
103.25K
View Stock
Market Cap
$392.65B
Dividends
2.5%
P/E Ratio
25.4
Revenue
$30.2B
-5.2%
Net Income
$6.83B
-7.8%
Profit Margin
+22.6%
Employees
103.25K
View Stock
Market Cap
$392.65B
Dividends
2.5%
P/E Ratio
25.4
Revenue
$30.2B
-5.2%
Net Income
$6.83B
-7.8%
Profit Margin
+22.6%
Employees
103.25K
View Stock
Market Cap
$392.65B
Dividends
2.5%
P/E Ratio
25.4
Revenue
$30.2B
-5.2%
Net Income
$6.83B
-7.8%
Profit Margin
+22.6%
Employees
103.25K
View Stock
Market Cap
$287.24B
Dividends
2.9%
P/E Ratio
23.6
Revenue
$14.1B
-5.0%
Net Income
$3.19B
-21.0%
Profit Margin
+22.7%
Employees
75.27K
View Stock
Market Cap
$287.24B
Dividends
2.9%
P/E Ratio
23.6
Revenue
$14.1B
-5.0%
Net Income
$3.19B
-21.0%
Profit Margin
+22.7%
Employees
75.27K
View Stock
Market Cap
$287.24B
Dividends
3.1%
P/E Ratio
21.8
Revenue
$14.1B
-5.0%
Net Income
$3.19B
-21.0%
Profit Margin
+22.7%
Employees
75.27K
View Stock
Market Cap
$287.24B
Dividends
3.1%
P/E Ratio
21.8
Revenue
$14.1B
-5.0%
Net Income
$3.19B
-21.0%
Profit Margin
+22.7%
Employees
75.27K
View Stock